5-Year Return on Invested Incremental Capital (5-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 5-year.
Compass Pathways's 5-Year ROIIC % for the quarter that ended in Dec. 2023 was -253.76%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Compass Pathways's 5-Year ROIIC % or its related term are showing as below:
CMPS's 5-Year ROIIC % is ranked worse than 96.09% of 562
companies
in the Healthcare Providers & Services industry
Industry Median: 1.335
vs CMPS: -253.76
Compass Pathways 5-Year ROIIC % Historical Data
The historical data trend for Compass Pathways's 5-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Compass Pathways's 5-Year ROIIC %
For the Medical Care Facilities subindustry, Compass Pathways's 5-Year ROIIC %, along with its competitors' market caps and 5-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Compass Pathways's 5-Year ROIIC % Distribution in the Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Compass Pathways's 5-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Compass Pathways's 5-Year ROIIC % falls into.
Compass Pathways 5-Year ROIIC % Calculation
Compass Pathways's 5-Year ROIIC % for the quarter that ended in Dec. 2023 is calculated as:
5-Year ROIIC %
=
5-Year Incremental Net Operating Profit After Taxes (NOPAT)**
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 5-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Compass Pathways 5-Year ROIIC % Related Terms
Thank you for viewing the detailed overview of Compass Pathways's 5-Year ROIIC % provided by GuruFocus.com. Please click on the following links to see related term pages.
Compass Pathways (Compass Pathways) Business Description
Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find better ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CMPS has been successfully added to your 